XAMIOL ® Calcipotriol + Betamethasone

XAMIOL ® is a drug based on Calcipotriol + Betamethasone

THERAPEUTIC GROUP: Antipsoriatics for topical use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications XAMIOL ® Calcipotriol + Betamethasone

XAMIOL ® is indicated for the treatment of scalp psoriasis in adults.

Mechanism of action XAMIOL ® Calcipotriol + Betamethasone

XAMIOL ® combines two very important active ingredients that are particularly effective in the treatment of psoriasis and have complementary biological and therapeutic activities.

More precisely:

Calcipotriol is a synthetic analogue of vitamin D which, by reprogramming the gene expression of keratinocytes, blocks its proliferation, inducing apoptosis, and directs its differentiation normalizing the histological features of the psoriatic lesion.
Betamethasone, on the other hand, also for topical use is able to reduce the expression of genes involved in the synthesis of inflammatory mediators, reducing the recruitment of leukocytes and lymphocytes and thus also exerting an antipruritic, vasoconstrictive as well as anti-inflammatory action.

Furthermore, the correct topical use of the drug makes the therapy safe, preventing the two active ingredients from reaching pharmacologically relevant systemic concentrations, thus reducing the risks linked instead to the classical systemic therapy with the aforementioned active ingredients.

Studies carried out and clinical efficacy

CALCIPOTRIOLO + BETAMETASONE: comparative therapeutic schemes

J Dermatolog Treat. 2013 May 23. [Epub ahead of print]

Clinical trial conducted on 855 patients which demonstrates how the application of XAMIOL twice a day against the "need" one is decidedly more effective and less associated with delays in the improvement of symptoms.

CALCIPOTRIOLO AND APOPTOSIS

Int J Dermatol. 2007 May; 46 (5): 468-74.

Molecular study that demonstrates how treatment with Calcipotriol can determine a reprogramming of gene expression with the control of the apoptotic process mediated by the balancing Bcl-2, P53, in favor of the programmed death of keratinocytes and lymphocytes.

XAMIOL EFFECTIVENESS AND SECURITY

Br J Dermatol. 2009 Jul; 161 (1): 159-66. doi: 10.1111 / j.1365-2133.2009.09116.x. Epub 2009 Mar 26.

Study demonstrating that once a day XAMIOL intake may be more effective and better tolerated than other more intense therapeutic schemes, in patients suffering from psoriasis of the scalp.

Method of use and dosage

XAMIOL ®

Topical gel with 50 mcg of Calcipotriol and 0.5 mg of Betamethasone per gram of product.

Dosages and timing of taking XAMIOL ® should be defined by your doctor based on the patient's physiopathological characteristics and the severity of his / her clinical picture.

Generally, it is recommended to apply the appropriate amount of gel directly on the area to be treated, once a day for about 4 weeks.

Warnings XAMIOL ® Calcipotriol + Betamethasone

Given the presence in XAMIOL ® of both Calcipotriol and Betamethasone, in order to reduce the risk of side effects, the patient in therapy should:

avoid the simultaneous use of other corticosteroid drugs;
periodically monitor the parameters of liver and kidney function, and those related to glucose metabolism;
avoid contact of the drug with injured skin;
avoid contact of the drug with eyes, mouth and mucosa;
clean hands thoroughly after each application;
avoid direct exposure to sunlight;
strictly follow the doctor's instructions.

PREGNANCY AND BREASTFEEDING

The absence of studies useful to clarify the safety profile of the association between Betamethasone and Calcipotriol for the health of the fetus and infant, inevitably extends the aforementioned contraindications to the use of XAMIOL ® also to pregnancy and the subsequent period of breastfeeding .

Interactions

The patient receiving XAMIOL ® should avoid the application of other products topically in the same treated skin area, especially with corticosteroids.

Contraindications XAMIOL ® Calcipotriol + Betamethasone

The use of XAMIOL ® is contraindicated in patients hypersensitive to the active ingredient or to one of its excipients, in patients with altered calcium metabolism, in the forms of guttate, erythrodermic, exfoliative and pustular psoriasis, in patients suffering from severe hepatic impairment and renal and in patients with skin infections, skin atrophy, capillary fragility, acne, ulcers, wounds and perianal itching.